Provider file · dose-tiered with brand hand-off

ShedRx review (2026): the file, on record

ON RECORD · AUDIT QUEUEDUpdated August 17, 2026Field dictionary

Billing model: Dose-tiered with brand hand-off. This file runs on published rates — no one has re-walked this checkout this cycle, and the page says so wherever a number appears. The audited benchmark for the whole field is the NexLife file; every figure below should be read against it.

What it costs, on record

Compounded tirzepatide publishes from about $199 at entry doses, tiering toward $299 as titration proceeds — a realistic year lands between $2,400 and $3,000+. The genuinely useful feature is the hand-off lane to brand medication when insurance clears prior authorization.

Fits if — and watch for

Fits if you expect to convert to covered Zepbound mid-journey and want a program built for that switch. Watch the step-up — budget the maintenance tier, not the door price, because the schedule delivers the increase without announcing one.

File status

Every figure above is an on-record published rate, filed in the open dataset with its source URL. An audit — a human re-walking the live checkout — converts this file's numbers to stamped figures or corrections; until then, under the site's iron rule, any audited competitor figure outranks these regardless of size. Compounded medications are not FDA-approved, and whether therapy fits you is a licensed clinician's call.

Open ShedRx ↗ partner link, sponsored tag attached · how the money works